Open AccessImprovement of survival in Korean breast cancer patients over a 14-year period: A large-scale single-center study
Author(s) -
Hakyoung Kim,
Sae Byul Lee,
Jisun Kim,
Il Yong Chung,
Hee Jeong Kim,
Beom Seok Ko,
Jong Won Lee,
Byung Ho Son,
Sei Hyun Ahn
Publication year - 2022
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0265533
Subject(s) - breast cancer , medicine , oncology , cancer , survival rate , survival analysis , triple negative breast cancer , distant metastasis , metastasis
Purpose The aim of this study was to evaluate the chronological changes over 14 years in the survival of Korean patients with breast cancer. We also sought to investigate the factors that may have influenced the changes in survival rate. Materials and methods We retrospectively analyzed 17,776 breast cancer patients who were treated at Asan Medical Center between January 2000 and December 2013. Patient information was collected from the Asan database, including age at diagnosis, clinical manifestation, pathology report, types of treatment and modality, types of recurrence, and follow-up period. We classified the patients into two cohorts according to the year of their surgery (P1: 2000–2007 and P2: 2008–2013) and compared survival and recurrence between both cohorts. Results We observed that patients treated more recently had better survival outcomes. The 5-year breast cancer-specific survival increased from 94.0% in P1 to 96.6% in P2 (p<0.001), and the 5-year disease-free survival increased from 87.9% in P1 to 91.2% in P2 (p<0.001). When analyzed by type of recurrence, distant metastasis-free survival increased to a significant degree. In subgroup analysis by the subtypes of breast cancer, the survival rates improved in all of the subtypes except triple negative breast cancer, and the improvement was more prominent in subtypes with overexpressed human epidermal growth factor receptor 2. Conclusion This study showed improvement in breast cancer survival over the succeeding years, which is consistent with the advancement in systemic therapy.